<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
     xmlns:dc="http://purl.org/dc/elements/1.1/"
     xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
     xmlns:admin="http://webns.net/mvcb/"
     xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
     xmlns:content="http://purl.org/rss/1.0/modules/content/"
     xmlns:media="http://search.yahoo.com/mrss/">
<channel>
<title>My American Doctor &#45; : Prostate Cancer</title>
<link>https://myamericandoctor.in/rss/category/Prostate-Cancer</link>
<description>My American Doctor &#45; : Prostate Cancer</description>
<dc:language>en</dc:language>
<dc:rights>@myamericandoctor.in</dc:rights>

<item>
<title>When Prostate Cancer Stops Responding to Hormone Therapy: What Every Man Needs to Know About Castration&#45;Resistant Prostate Cancer</title>
<link>https://myamericandoctor.in/castration-resistant-prostate-cancer-treatment-options-india</link>
<guid>https://myamericandoctor.in/castration-resistant-prostate-cancer-treatment-options-india</guid>
<description><![CDATA[ Castration-resistant prostate cancer (CRPC) occurs when prostate cancer continues to grow despite castrate levels of testosterone. It is not a final diagnosis but a new phase of treatment with multiple approved therapies available — including next-generation androgen receptor inhibitors, chemotherapy, lutetium-177 PSMA-617 (Pluvicto), PARP inhibitors for patients with DNA repair gene mutations, and bone-targeted treatments. Early comprehensive evaluation — including restaging imaging, genetic testing, and specialist consultation — is essential. The ASCO 2025/2026 Living Guideline, the most current authoritative guidance on mCRPC, emphasizes personalized treatment sequencing based on prior therapy, genetic profile, and performance status. Men who engage actively with their oncology team at CRPC diagnosis consistently achieve better outcomes. ]]></description>
<enclosure url="https://myamericandoctor.in/uploads/images/202602/image_870x580_69a0dd7b3f2e8.jpg" length="146784" type="image/jpeg"/>
<pubDate>Fri, 27 Feb 2026 05:24:24 +0530</pubDate>
<dc:creator>My American Doctor</dc:creator>
<media:keywords>castration resistant prostate cancer, CRPC treatment options India, prostate cancer hormone therapy stopped working, PSA rising on ADT, metastatic CRPC treatment, enzalutamide abiraterone darolutamide CRPC, PARP inhibitors prostate cancer BRCA, lutetium PSMA-617 Pluvicto prostate cancer, non-metastatic CRPC treatment, ASCO CRPC guidelines 2025 2026, prostate cancer second opinion India, advanced prostate cancer management, PSMA PET scan prostate cancer India, BRCA prostate cancer genetic testing</media:keywords>
</item>

<item>
<title>The PSA Dilemma: What Your Doctor May Not Be Telling You About Prostate Cancer Screening</title>
<link>https://myamericandoctor.in/psa-prostate-cancer-screening-controversy</link>
<guid>https://myamericandoctor.in/psa-prostate-cancer-screening-controversy</guid>
<description><![CDATA[ Prostate cancer is the second most common cancer in men globally, yet its primary screening tool — the PSA blood test — remains deeply controversial. While PSA testing can detect cancer early and reduce mortality, it is not cancer-specific, frequently producing false positives that trigger unnecessary biopsies and overtreatment. Major medical bodies disagree on screening guidelines, but universally recommend shared decision-making between patient and doctor. Higher-risk men — those with family history, of African descent, or carrying BRCA2 mutations — should consider earlier screening. Emerging technologies like MRI-guided biopsies and advanced biomarkers are improving precision and gradually shifting the benefit-harm balance toward screening. ]]></description>
<enclosure url="https://myamericandoctor.in/uploads/images/202602/image_870x580_699521fb62b29.jpg" length="132802" type="image/jpeg"/>
<pubDate>Wed, 18 Feb 2026 07:51:01 +0530</pubDate>
<dc:creator>admin</dc:creator>
<media:keywords>Primary: prostate cancer screening India, PSA test controversy, prostate cancer PSA test, prostate cancer screening guidelines, when to get PSA test, prostate cancer early detection Secondary: PSA false positive, overdiagnosis prostate cancer, active surveillance prostate cancer, prostate cancer screening age, BRCA2 prostate cancer risk, MRI guided prostate biopsy Long-tail: should I get a PSA test at 50, is PSA test reliable for prostate cancer, prostate cancer screening shared decision making</media:keywords>
</item>

</channel>
</rss>